Navigation Links
SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today.
Date:7/23/2014

OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., July 23, 2014 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in translational preclinical research, today unveiled their new logo and corporate website (found at www.surpassinc.com), signaling the transformation of Surpass' corporate culture to one where our team is an integrated innovation partner for our customers. This press release comes on the heels of the announcement last week that two integral hires were added to the Silicon Valley Team:  David Craig, a veteran preclinical scientist and expert veterinary interventionalist, and Benigno Mills, a veterinary surgical and interventional specialist.

Photo - http://photos.prnewswire.com/prnh/20140723/129682

"The launch of our new logo and website signifies the beginning of a new era for Surpass. We have refined our company's culture in response to the ever-changing needs of our customers. What customers needed 5 or 10 years ago is very different from today. With increasing pressures on the healthcare dollar, every stakeholder in the medical innovation continuum needs to work in concert. Long gone are the days where engineering, preclinical research, regulatory, and other entities operate separately. To stay competitive, the life science industry as a whole needs to be connected in ways that enable us to develop new medical solutions faster, better, and cheaper. This only happens in a true team environment where the task is supreme," said Dr. Tim Pelura, President and CEO of Surpass. "We at Surpass bring much more to our client partners. We provide insightful solutions and support every step of the way as a valuable extension of your product development team. Our People are Your Team. Surpass customizes our services to meet your specific project need. We're changing the rules for a better way to get from concept to reality."

"The new logo signifies Surpass' commitment to be an integrated preclinical partner for our customers - two vibrantly colored hemispheres coming together as one team," commented Denise Forkey, Senior Director of Marketing and Corporate Communications for Surpass. "The hemispheres are joined by an artistic rendition of the EKG wave signifying the importance and vitality of the work we perform within the global life science community every day at Surpass."

To hear Dr. Pelura talk about how Surpass partners with our clients to advance life-saving products into the hands of physicians and patients, visit our website.

About Surpass

Our innovative approach to preclinical research goes beyond the ordinary. We're changing the rules for a better way to get from concept to reality.

Surpass is a trusted contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.

Surpass' breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Greater Twin Cities) or (650) 477-8267 (Silicon Valley).

Visit www.surpassinc.com for more information.  Connect with Surpass, Inc. on Linked In, YouTube, Twitter, Facebook, and Google+.

Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101, dforkey@surpassinc.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Surpass, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022
2. Introducing the Nanotrac Wave Q, a Particle Size Analyzer that Measures with Unsurpassed Accuracy and Repeatability
3. CAS REGISTRY(SM) surpasses 75 million small molecules
4. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
5. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
6. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
7. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
8. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
9. The US Market For Arthroscopy Devices Will Expand Quickly To Surpass $1 Billion By 2021
10. Omnicell and Codonics Partner to Deliver Unsurpassed Anesthesia Medication Management Compliance
11. John Velyvis MD Surpasses 550 Robotic Assisted Partial Knee Resurfacing Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology:
(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):